The March 2026 quarter presents a tale of two narratives for Glenmark. On one hand, the company has achieved remarkable year-on-year expansion from the depressed base of Q4 FY25, when net profit stood at a meagre ₹4.65 crores. On the other, the sequential contraction from the exceptional Q3 FY26 performance—which benefited from one-time gains and exceptional operational performance—raises questions about underlying business momentum. The pharmaceutical major's stock has delivered stellar returns over longer time horizons, appreciating 45.66% over the past year and an impressive 256.11% over three years, significantly outperforming the Sensex and the broader pharmaceuticals sector.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | Operating Margin |
|---|---|---|---|---|---|
| Mar'26 | 3,770.59 | -3.33% | 301.41 | -25.25% | 20.28% |
| Dec'25 | 3,900.62 | -35.49% | 403.21 | -33.94% | 22.37% |
| Sep'25 | 6,046.87 | +85.23% | 610.35 | +1,202.22% | 39.30% |
| Jun'25 | 3,264.44 | +0.25% | 46.87 | +907.96% | 18.98% |
| Mar'25 | 3,256.20 | -3.88% | 4.65 | -98.66% | 17.42% |
| Dec'24 | 3,387.55 | -1.35% | 347.96 | -1.76% | 18.18% |
| Sep'24 | 3,433.80 | — | 354.21 | — | 17.70% |
Financial Performance: Sequential Moderation After Stellar Q3
Glenmark's Q4 FY26 revenue of ₹3,770.59 crores represented a 3.33% sequential decline from Q3 FY26's ₹3,900.62 crores, though it remained 15.80% higher than the year-ago quarter. The sequential softness follows an unusual Q3 FY26 that saw sales spike to ₹6,046.87 crores—an 85.23% quarter-on-quarter surge driven by exceptional circumstances. Normalising for this anomaly, Q4's performance appears more consistent with the company's underlying run-rate, hovering around the ₹3,700-3,900 crore quarterly revenue band.
Operating profit margins contracted to 20.28% in Q4 FY26 from 22.37% in the previous quarter, reflecting a 209 basis point sequential compression. This margin normalisation was partly attributable to the unwinding of Q3's exceptional profitability (39.30% margin) and increased employee costs, which rose to ₹887.44 crores from ₹841.40 crores quarter-on-quarter. Despite the sequential decline, Q4's operating margin remained 288 basis points higher than the 17.42% recorded in Q4 FY25, indicating sustained operational improvements on an annual basis.
Net profit margins stood at 8.01% in Q4 FY26, down from 10.37% in Q3 FY26 but substantially higher than the 0.14% recorded in Q4 FY25. The company's other income moderated significantly to ₹189.08 crores in Q4 FY26 from ₹44.47 crores in Q3 FY26, suggesting one-time gains or treasury income volatility. Interest costs remained relatively stable at ₹42.60 crores, whilst depreciation was recorded at ₹147.91 crores, reflecting the company's ongoing capital investments in manufacturing capabilities.
Operational Excellence: Capital Efficiency Reaches New Heights
Despite the sequential earnings moderation, Glenmark's operational efficiency metrics paint an encouraging picture of underlying business quality. The company's return on capital employed (ROCE) for the half-year period reached an impressive 40.16%—the highest level recorded in recent periods—demonstrating exceptional capital productivity. This represents a significant improvement from the average ROCE of 19.22% over the past five years, indicating that management's strategic initiatives are translating into superior returns.
The company's return on equity (ROE) stood at 26.86% for the latest period, substantially higher than the five-year average of 12.43%. This elevation in ROE reflects improved profitability and more efficient utilisation of shareholder capital. Whilst Glenmark's ROE of 12.43% on a normalised basis remains below some pharmaceutical peers—Mankind Pharma at 15.98% and Alkem Laboratories at 16.88%—the recent surge to 26.86% suggests the company is closing this gap rapidly.
Glenmark's balance sheet strength remains a cornerstone of its investment appeal. The company maintains a net debt-to-equity ratio of -0.06, effectively positioning it as a net cash company. Long-term debt stood at ₹512.70 crores as of March 2025, whilst current assets of ₹9,295.47 crores substantially exceeded current liabilities of ₹5,967.02 crores, providing ample liquidity cushion. The debt-to-EBITDA ratio of 1.37 indicates low leverage, with the company generating sufficient cash flows to service its modest debt obligations comfortably. Interest coverage, measured by EBIT-to-interest ratio, averaged a healthy 7.97 times over recent periods.
Capital Efficiency Breakthrough
ROCE Surge: Glenmark's half-year ROCE of 40.16% represents the highest level achieved in recent years, more than doubling the five-year average of 19.22%. This exceptional capital efficiency demonstrates that the company is generating ₹40.16 in operating profit for every ₹100 of capital employed, reflecting improved asset utilisation and operational leverage. The company's debt-to-equity ratio of -0.06 indicates it is essentially a net cash company, providing financial flexibility for growth investments and shareholder returns.
Revenue Mix and Geographic Diversification
Whilst specific geographic and product segment breakdowns were not detailed in the quarterly results, Glenmark's business model encompasses three key revenue streams: branded generics in emerging markets, generics in developed markets (particularly the United States), and active pharmaceutical ingredients (APIs). The company has historically derived substantial revenues from its US generics business, which can experience quarterly volatility due to product launch timing, competitive intensity, and regulatory approvals.
The full-year FY25 performance provides context for the quarterly fluctuations. Annual net sales reached ₹13,321 crores, representing 12.80% growth over FY24's ₹11,813 crores. Operating profit (excluding other income) improved to ₹2,351 crores with a margin of 17.60%, recovering from FY24's depressed 10.10% margin. This annual improvement suggests that underlying business momentum remains intact despite quarterly variations.
Peer Comparison: Competitive Positioning in Pharmaceuticals
Glenmark's valuation metrics present an interesting contrast within the pharmaceutical sector. Trading at a price-to-earnings ratio of 21.83 times trailing twelve-month earnings, the stock commands a discount to the broader pharmaceutical industry average P/E of 33 times. This valuation gap reflects market concerns about growth consistency and competitive pressures in key markets, particularly the United States generics segment.
| Company | P/E (TTM) | P/BV | ROE % | Div Yield % | Debt/Equity |
|---|---|---|---|---|---|
| Glenmark Pharma | 21.83 | 5.87 | 12.43 | 0.23 | -0.06 |
| Mankind Pharma | 47.04 | 5.83 | 15.98 | 0.04 | 0.26 |
| Aurobindo Pharma | 23.33 | 2.19 | 9.95 | 0.28 | -0.07 |
| Laurus Labs | 83.52 | 14.01 | 14.59 | 0.15 | 0.45 |
| Alkem Laboratories | 25.98 | 4.54 | 16.88 | 0.97 | -0.03 |
From a price-to-book value perspective, Glenmark trades at 5.87 times, broadly in line with Mankind Pharma (5.83 times) but at a premium to Aurobindo Pharma (2.19 times) and Alkem Laboratories (4.54 times). This P/BV ratio appears justified given the company's improving ROE trajectory and net cash position. Glenmark's dividend yield of 0.23% remains modest compared to Alkem's 0.97%, reflecting a conservative payout ratio of 6.74% as management prioritises reinvestment in research and development and business expansion.
The company's competitive advantage lies in its strong balance sheet—evidenced by negative debt-to-equity of -0.06—which provides financial flexibility unavailable to more leveraged peers. Whilst Glenmark's historical ROE of 12.43% trails Mankind Pharma (15.98%) and Alkem Laboratories (16.88%), the recent surge to 26.86% suggests the profitability gap is narrowing rapidly. The lower P/E multiple of 21.83 times versus Mankind's 47.04 times and Laurus Labs' 83.52 times indicates the market has yet to fully recognise Glenmark's improved earnings power.
Valuation Analysis: Attractive Entry Point Despite Near-Term Volatility
Glenmark's current valuation presents a compelling risk-reward proposition for long-term investors. At ₹2,184.90, the stock trades at a P/E ratio of 21.83 times, representing a 34% discount to the pharmaceutical sector average of 33 times. The company's PEG ratio of 0.17 suggests the stock is significantly undervalued relative to its growth potential, as ratios below 1.0 typically indicate attractive valuations.
The stock's enterprise value-to-EBITDA multiple of 13.36 times appears reasonable given the sector dynamics and Glenmark's improving profitability trajectory. With an EV-to-sales ratio of 3.60 times, the company trades at a premium to some generic-focused peers but at a discount to specialty pharmaceutical companies, reflecting its hybrid business model. The price-to-book value of 5.87 times, whilst elevated in absolute terms, appears justified by the improving ROE of 26.86% and the company's net cash position.
Glenmark's valuation grade has fluctuated between "Attractive," "Fair," and "Expensive" over the past year, currently settling at "Fair" as of October 2025. The stock reached a 52-week high of ₹2,471.05 and currently trades 11.58% below that peak, having appreciated 50.84% from its 52-week low of ₹1,448.50. This positioning suggests the stock has captured much of its recovery rally but retains upside potential if operational improvements continue.
Shareholding Pattern: Institutional Confidence Building
Glenmark's shareholding structure reveals increasing institutional interest, with total institutional holdings reaching 39.67% as of March 2026. Foreign institutional investors (FIIs) held 20.34% of equity, marking a sequential increase of 1.14 percentage points from December 2025's 19.20%. This uptick in FII ownership suggests growing international investor confidence in the company's turnaround story, particularly following the strong nine-month performance in FY26.
| Quarter | Promoter % | FII % | Change | MF % | Change | Insurance % |
|---|---|---|---|---|---|---|
| Mar'26 | 46.65 | 20.34 | +1.14 | 16.80 | -1.06 | 1.00 |
| Dec'25 | 46.65 | 19.20 | -1.53 | 17.86 | +1.55 | 1.03 |
| Sep'25 | 46.65 | 20.73 | +0.11 | 16.31 | +0.76 | 0.66 |
| Jun'25 | 46.65 | 20.62 | -2.54 | 15.55 | +2.69 | 0.46 |
| Mar'25 | 46.65 | 23.16 | — | 12.86 | — | 0.43 |
Mutual fund holdings stood at 16.80% in Q4 FY26, declining marginally by 1.06 percentage points from the previous quarter's 17.86%. This modest reduction follows a period of aggressive accumulation, with mutual fund ownership expanding from 12.86% in March 2025 to a peak of 17.86% in December 2025—a 5 percentage point increase over nine months. The presence of 36 mutual fund schemes holding Glenmark shares indicates broad-based institutional interest rather than concentrated bets.
Promoter holding remained stable at 46.65% throughout the past five quarters, with the Saldanha Family Trust controlling 45.44% and individual family members holding the balance. The absence of any promoter pledging provides comfort regarding financial stability and alignment of interests with minority shareholders. Non-institutional holdings declined to 13.68% from 14.02% sequentially, suggesting retail investors may have booked profits following the stock's strong rally.
Stock Performance: Exceptional Long-Term Returns with Recent Consolidation
Glenmark's stock has delivered stellar returns across most time horizons, significantly outperforming both the Sensex and the broader pharmaceutical sector. Over the past year, the stock appreciated 45.66% compared to the Sensex's decline of 8.26%, generating alpha of 53.92 percentage points. This outperformance extended across longer periods, with two-year returns of 88.23% (alpha: 87.30 percentage points) and three-year returns of 256.11% (alpha: 236.76 percentage points).
| Period | Stock Return | Sensex Return | Alpha | Sector Return |
|---|---|---|---|---|
| 1 Week | -7.07% | -1.79% | -5.28% | — |
| 1 Month | -9.17% | -2.94% | -6.23% | — |
| 3 Months | +2.89% | -6.97% | +9.86% | — |
| 6 Months | +10.38% | -12.32% | +22.70% | — |
| 1 Year | +45.66% | -8.26% | +53.92% | +8.26% |
| 2 Years | +88.23% | +0.93% | +87.30% | — |
| 3 Years | +256.11% | +19.35% | +236.76% | — |
| 5 Years | +255.27% | +43.97% | +211.30% | — |
However, recent price action suggests a period of consolidation. The stock declined 7.07% over the past week and 9.17% over the past month, underperforming the Sensex during both periods. This near-term weakness follows the stock's approach to its 52-week high of ₹2,471.05, with profit-booking evident amongst short-term traders. The stock currently trades below its 5-day, 20-day, and 50-day moving averages, indicating near-term technical weakness, though it remains above its 100-day and 200-day moving averages, preserving the longer-term uptrend.
With a beta of 1.20, Glenmark exhibits higher volatility than the broader market, amplifying both gains and losses during market swings. The stock's volatility of 31.08% over the past year classifies it as a "medium risk, high return" investment, with a positive Sharpe ratio of 1.47 indicating that the returns adequately compensate for the risk undertaken. Technical indicators present a mixed picture, with weekly MACD turning mildly bearish whilst monthly MACD remains bullish, suggesting short-term consolidation within a longer-term uptrend.
Investment Thesis: Quality Improving, Valuation Reasonable
Glenmark's investment case rests on four key pillars: improving financial trends, good fundamental quality, attractive valuation, and moderating technical momentum. The company's financial trend assessment stands at "Positive" as of March 2026, supported by exceptional half-year ROCE of 40.16%, nine-month sales growth, and the lowest debt-to-equity ratio in recent periods. These metrics indicate operational improvements are taking root despite quarterly fluctuations.
The quality grade of "Good" reflects the company's strong balance sheet fundamentals, including zero net debt, healthy interest coverage of 7.97 times, and robust institutional holdings of 39.67%. Whilst historical ROE of 12.43% trails some peers, the recent surge to 26.86% demonstrates improving capital efficiency. The absence of promoter pledging and consistent promoter holding at 46.65% provide governance comfort.
From a valuation perspective, the stock's P/E ratio of 21.83 times represents a 34% discount to the sector average, whilst the PEG ratio of 0.17 suggests significant undervaluation relative to growth prospects. The combination of improving fundamentals and reasonable valuation supports the current "BUY" rating with a score of 71 out of 100. Technical indicators show a "Mildly Bullish" trend, with near-term consolidation likely before the next leg of the uptrend resumes.
Key Strengths and Risk Factors
KEY STRENGTHS
- Exceptional Capital Efficiency: Half-year ROCE of 40.16% represents the highest level in recent periods, demonstrating superior asset utilisation and operational leverage
- Net Cash Position: Debt-to-equity ratio of -0.06 provides financial flexibility for growth investments, acquisitions, and shareholder returns without leverage constraints
- Strong Institutional Backing: Total institutional holdings of 39.67% with 346 FII investors and 36 mutual fund schemes indicate broad-based confidence in the turnaround story
- Improving Profitability: ROE surged to 26.86% from a five-year average of 12.43%, reflecting enhanced earnings power and capital efficiency
- Attractive Valuation: P/E of 21.83x represents a 34% discount to sector average, whilst PEG ratio of 0.17 suggests significant undervaluation relative to growth
- Diversified Revenue Base: Presence across branded generics, US generics, and APIs provides revenue stability and reduces dependence on single markets
- Zero Promoter Pledging: Clean governance with stable 46.65% promoter holding and no pledged shares demonstrates financial stability and alignment
KEY CONCERNS
- Sequential Earnings Volatility: Q4 FY26 net profit declined 25.25% QoQ, raising questions about sustainability of Q3's exceptional performance and underlying business momentum
- Revenue Growth Inconsistency: Quarterly sales fluctuated significantly (from ₹3,264 crores to ₹6,046 crores and back to ₹3,770 crores), indicating lumpy revenue recognition patterns
- US Generics Competition: Intense pricing pressure and competitive intensity in the US market pose ongoing margin challenges and revenue visibility concerns
- Lower ROE vs Peers: Historical ROE of 12.43% trails Mankind Pharma (15.98%), Alkem Labs (16.88%), and sector leaders, suggesting efficiency gaps remain
- Modest Dividend Yield: Yield of 0.23% with a conservative 6.74% payout ratio provides limited income for yield-seeking investors
- Regulatory Risks: Pharmaceutical manufacturing faces ongoing USFDA inspection risks, with potential observations impacting product approvals and facility operations
- Near-Term Technical Weakness: Stock trading below 5-day, 20-day, and 50-day moving averages suggests consolidation phase with potential for further correction
Outlook: What to Watch in Coming Quarters
POSITIVE CATALYSTS
- Sustained ROCE Above 30%: Maintenance of exceptional capital efficiency would validate operational improvements and support premium valuations
- US Product Approvals: New ANDA approvals and product launches in the US market could drive revenue growth and market share gains
- Margin Expansion: Operating margins stabilising above 20% on a consistent basis would demonstrate pricing power and cost management success
- Increasing FII Holdings: Continued accumulation by foreign institutional investors would provide stock price support and liquidity
- Debt Reduction: Further reduction of the modest ₹512.70 crore long-term debt would strengthen balance sheet and reduce financial risk
RED FLAGS TO MONITOR
- Continued Sequential Decline: If Q1 FY27 shows further profit contraction, it would indicate structural issues rather than one-time Q3 FY26 gains
- Margin Compression: Operating margins falling below 18% would signal pricing pressure and competitive challenges in key markets
- USFDA Observations: Any warning letters or import alerts from US regulators could disrupt product supplies and damage reputation
- FII Selling: Reversal of recent FII accumulation trend would indicate waning institutional confidence in the turnaround story
- Working Capital Deterioration: Increase in debtor days or inventory levels would indicate operational efficiency challenges
The Verdict: Compelling Value Play with Near-Term Volatility
Score: 71/100
For Fresh Investors: Glenmark presents an attractive entry opportunity for investors with a 12-18 month investment horizon. The combination of improving operational metrics—particularly the exceptional ROCE of 40.16%—strong balance sheet with net cash position, and reasonable valuation at 21.83x P/E creates a compelling risk-reward proposition. Accumulate on dips towards ₹2,000-2,100 levels for optimal entry, as near-term consolidation is likely given recent price weakness.
For Existing Holders: Continue holding with confidence. The sequential earnings moderation in Q4 FY26 appears to be normalisation after Q3's exceptional performance rather than structural deterioration. The underlying business momentum remains intact, evidenced by strong year-on-year comparisons and improving capital efficiency. Use any weakness below ₹2,000 to add to positions, whilst maintaining a 12-18 month holding period to capture the full benefits of operational improvements.
Fair Value Estimate: ₹2,450-2,550 (12-15% upside from current levels)
Rationale: The BUY rating reflects Glenmark's transformation from a highly leveraged, struggling pharmaceutical company to a net cash entity with improving profitability and exceptional capital efficiency. Whilst quarterly earnings volatility remains a concern—particularly the 25.25% sequential decline in Q4 FY26—the longer-term trajectory appears positive. The company's ROCE of 40.16% and ROE of 26.86% demonstrate that management's strategic initiatives are translating into superior returns on capital. At a P/E of 21.83x—representing a 34% discount to the sector—and a PEG ratio of 0.17, the stock offers attractive value for patient investors willing to look through near-term fluctuations. The strong institutional backing, zero promoter pledging, and net cash position provide downside protection, whilst improving operational metrics offer upside potential as the market recognises the earnings power improvement.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results, and all investments carry risk of loss.
